KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Other financing activities (2016 - 2023)

Historic Other financing activities for Travere Therapeutics (TVTX) over the last 13 years, with Q4 2023 value amounting to -$259000.0.

  • Travere Therapeutics' Other financing activities changed N/A to -$259000.0 in Q4 2023 from the same period last year, while for Sep 2024 it was -$259000.0, marking a year-over-year increase of 7693.68%. This contributed to the annual value of -$1.4 million for FY2023, which is 11398.5% down from last year.
  • Travere Therapeutics' Other financing activities amounted to -$259000.0 in Q4 2023.
  • Over the past 5 years, Travere Therapeutics' Other financing activities peaked at $9.5 million during Q1 2022, and registered a low of -$6.1 million during Q4 2021.
  • In the last 4 years, Travere Therapeutics' Other financing activities had a median value of -$259000.0 in 2023 and averaged $396000.0.
  • Its Other financing activities has fluctuated over the past 5 years, first plummeted by 1553.61% in 2019, then tumbled by 16573.6% in 2023.
  • Quarter analysis of 4 years shows Travere Therapeutics' Other financing activities stood at $772000.0 in 2019, then plummeted by 890.67% to -$6.1 million in 2021, then skyrocketed by 106.45% to $394000.0 in 2022, then tumbled by 165.74% to -$259000.0 in 2023.
  • Its Other financing activities was -$259000.0 in Q4 2023, compared to -$260000.0 in Q3 2023 and -$259000.0 in Q2 2023.